Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Patents for NLRP3 inflammasome-inhibiting compounds granted in US and Europe

19
SHARES

Inflazome has announced that the US and EU will grant patents to their NLRP3 inflammasome inhibiting compounds.

many file labels with patents in the centre

Inflazome have announced that the US Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have granted approval to patents for the company’s small molecule compounds that show useful activity in inhibiting NLRP3 inflammasome activation.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The patent application WO 2016/131098 will be accepted by the USPTO as US 10,538,487 on 21 January 2020 and by the EPO as EP 3,259,253 on 15 January 2020.

The pharma business currently has two NLRP3 inflammasome inhibiting compounds in Phase I trials, Inzomelid and Somalix. These treatments can be used in a range of disorders, including Parkinson’s, Alzheimer’s and motor neurone disease, where inflammation is a key factor and starts or progresses due to the NLRP3 inflammasome.

According to the company, it also reinforces their position in discovering targeted therapies for inflammatory-driven diseases.

Matt Cooper, Chief Executive Officer of Inflazome, commented: “The granting of these pioneering patents marks another milestone for Inflazome and strengthens our intellectual property (IP) portfolio. The patents granted in the US and Europe cover our lead clinical candidate, Inzomelid. Both Inzomelid and our second drug, Somalix, are in the final stages of Phase I safety and tolerability trials for inflammatory diseases. We look forward to driving these drugs into further trials to help people with debilitating diseases.”

Share via
Share via